← Russell 3000 cross-section

PGNY Progyny, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$2.0bn
Revenue TTM
$1.3bn
Net income TTM
$79m
Free cash flow
$178m
Composite score
75.6
Sector rank
#1642

Valuation

P / E
25.6
EV / EBITDA
15.1
EV / sales
1.4
FCF yield
8.87%
Earnings yield vs 10-yr
-0.82pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.0%
EBITDA margin
9.0%
ROE
17.4%
ROIC
51.8%
Revenue growth
5.5%

Insider activity, last 90 days

Net open-market
$-0.48m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Fertility Benefits Solution Revenue Progyny primarily generates revenue through its fertility benefits solution, in which Progyny provides self-insured enterprise entities (“clients”) and their employees and partners (together, “members”) with fertility benefits. PEPM fees represented 1% of our total revenue for the six months ended June 30, 2026 and 2025. Our revenue in a given year is determined by the utilization, including rate of consumption and mix, of our fertility benefits and Progyny Rx solutions by our members as well as the number of members enrolled in our clients’ benefits plans. …Progyny, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →